Traws药业完成Ratutrelvir在适用与不适用Paxlovid®的新冠患者中的临床研究入组;宣布计划为Tivoxavir Marboxil新增季节性流感预防性治疗适应症

美股速递
Jan 26

Traws药业已顺利完成其候选药物Ratutrelvir针对适用及不适用Paxlovid®的新冠病毒感染者的临床试验患者招募工作。

与此同时,该公司宣布将拓展其另一款药物Tivoxavir Marboxil的适应症范围,计划将其开发为季节性流感的预防性治疗方案。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10